𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cellular changes during the infusion of high dose intravenous immunoglobulin

✍ Scribed by Newland, A. C. ;Macey, M. G. ;Veys, P. A.


Publisher
Springer-Verlag
Year
1989
Weight
633 KB
Volume
59
Category
Article
ISSN
1432-0584

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


The treatment of haemophilia a inhibitor
✍ Seifried, E. ;Gaedicke, G. ;Pindur, G. ;Rasche, H. πŸ“‚ Article πŸ“… 1984 πŸ› Springer-Verlag βš– 296 KB

In patients with Haemophilia A, the development of inhibitor is a life-threatening complication of treatment. These patients are at high risk for dangerous bleeding as a result of this acquired resistance to human Factor VIII concentrate. Although treatment of bleeding complications has been improve

High-dose intravenous immunoglobulins in
✍ U. Wintergerst; K. Niinivaara-Kreuzer; G. Notheis; K. Auberger; C. BrΓΌckmann; S. πŸ“‚ Article πŸ“… 1994 πŸ› Springer 🌐 English βš– 385 KB

In children infected with human immunodeficiency virus (HIV) placebo-controlled trials with intravenous immunoglobulins have resulted in a significant reduction in morbidity; however, the results of small trials in adolescents and adults have been inconsistent. In this study 17 HIV-infected hemophil

The treatment of atopic dermatitis with
✍ S. Jolles; J. Hughes; M. Rustin πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 225 KB

## Abstract There are few reports of the use of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of atopic dermatitis (AD). We describe our experience using this therapy in three patients with severe AD, all of whom had steroid-related side-effects. These patients received either Alph

Combined hormonal therapy with high-dose
✍ Juan C. Cervellino; Carlos E. Araujo; Claudia Pirisi; Oscar Podskubka; Eduardo M πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 335 KB

Fifty-one patients with stage D prostate cancer, who had failed primary hormone treatment, were treated with diethylstilbestrol diphosphate (DES-DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A). In group B, patients were treated with DES-DP as in A, plus vindesine (VND) 3 mg/m2 int